Meeting Banner
Abstract #0067

Differentiation Between Progressive Disease and Treatment Necrosis in Patients with Glioblastoma using Dynamic Contrast Enhancement MRI

Moran Artzi 1,2 , Gilad Liberman 1,3 , Guy Nadav 1,4 , Deborah T Blumenthal 5 , Felix Bokstein 5 , Orna Aizenstein 1 , and Dafna Ben Bashat 1,6

1 Functional Brain Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3 Department of Chemical Physics, Weizmann Institute, Rehovot, Israel, 4 Faculty of Engineering, Tel Aviv University, Tel Aviv, Israel, 5 Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 6 Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel

Differentiation between progressive-disease (PD) and treatment-necrosis (TN) in patients with Glioblastoma remains a major clinical challenge. In this study the enhanced tumor area was automatically identified from the raw DCE data using ICA. Voxel-based classification was performed using SVM based on the DCE pharmacokinetic parameters in eighteen patients scanned longitudinally (total of 60 MRI scans). Significant differences were obtained between transfer-constants, plasma-volume and bolus-arrival-time in the different tissue classes (PD and TN), and compared to NAWM. High sensitivity (89.3%) and specificity (89.4%) were obtained using two-fold cross-validation design. Classification results were validated by a senior neuro-radiologist and supported by MRS.

This abstract and the presentation materials are available to members only; a login is required.

Join Here